Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Investment demonstrates confidence in America’s commitment to science and innovation
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Strengthening capabilities in Peptide Therapeutics and CDMO services
Raichur site is the group’s largest API facility and part of a wider network of seven sites
The company offers customized formulations tailored to align with each brand’s identity and consumer needs
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Overall investment in the US facility is estimated around US$50 million
Subscribe To Our Newsletter & Stay Updated